8.27

2.71% -0.23

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $8.27, with a volume of 3.72M. It is down -2.71% in the last 24 hours and down -22.35% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Previous Close:

$8.50

Open:

$8.48

24h Volume:

3.72M

Relative Volume:

0.54

Market Cap:

$1.92B

Revenue:

$510.17M

Net Income/Loss:

$146.93M

P/E Ratio:

13.81

EPS:

0.599

Net Cash Flow:

$27.51M

1W Performance:

+1.22%

1M Performance:

-22.35%

6M Performance:

-46.85%

1Y Performance:

-56.93%

1-Day Range:

$8.20

$8.535

1-Week Range:

$7.81

$8.79

52-Week Range:

$7.2101

$22.37

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1101)

Industry

Biotechnology (612)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

647

Twitter

@AdmaBiologics

Next Earnings Date

2026-05-06

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	8.27	1.97B	510.17M	146.93M	27.51M	0.599
VRTX Vertex Pharmaceuticals Inc	436.95	114.32B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	698.25	74.74B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	799.32	51.13B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	286.98	39.18B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	145.66	31.78B	742.00K	-1.37B	-1.07B	-7.0731

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Mar-26-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

May 15, 2026

How Channel Stuffing Probes and ASCENIV’s Pediatric Expansion Will Impact ADMA Biologics (ADMA) Investors - Yahoo Finance

May 15, 2026

ADMA Biologics (ADMA) price target decreased by 26.10% to 17.08 - MSN

May 15, 2026

May 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc.ADMA - PR Newswire

May 14, 2026

ADMA Biologics IncCommon Stock (NQ: ADMA - FinancialContent

May 14, 2026

Here’s What Analysts Think About ADMA Biologics (ADMA) - Insider Monkey

May 14, 2026

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance

May 14, 2026

Adma biologics director Jerrold Grossman buys $100,125 in stock By Investing.com - Investing.com Nigeria

May 14, 2026

Adma biologics director Jerrold Grossman buys $100,125 in stock - Investing.com

May 14, 2026

ADMA Biologics (NASDAQ: ADMA) director adds 12,500 shares in open-market buy - Stock Titan

May 14, 2026

A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations - Sahm

May 14, 2026

חדשות למשקיעים ב-ADMA: אם סבלתם הפסדים ב-ADMA Biologics, Inc (נאסד"ק: ADMA), אתם מוזמנים ליצור קשר עם משרד רוזן עורכי הדין בנוגע לזכויותיכם - GlobeNewswire Inc.

May 14, 2026

May 13, 2026

ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ... - Caledonian Record

May 13, 2026

ADMA Investor News: If You Have Suffered Losses in ADMA - GlobeNewswire

May 13, 2026

ADMA Biologics Fair Value call delivered 50% gain despite volatility By Investing.com - Investing.com India

May 13, 2026

ADMA Biologics Fair Value call delivered 50% gain despite volatility - Investing.com UK

May 13, 2026

Adma Biologics director buys $100,125 of common stock - Investing.com UK

May 13, 2026

May 12, 2026

Adma Biologics director buys $100,125 of common stock By Investing.com - Investing.com Australia

May 12, 2026

Canaccord Cuts PT on ADMA Biologics Inc. (ADMA) But Remains a Buy on Shares - Insider Monkey

May 12, 2026

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action InvestigationADMA - PR Newswire

May 12, 2026

ADMA Biologics (ADMA) director adds 12,500 shares in open-market buy - Stock Titan

May 12, 2026

5 Best Small Cap Stocks to Buy for 10x Potential - Insider Monkey

May 12, 2026

Earnings call transcript: ADMA Biologics Q1 2026 results miss expectations By Investing.com - Investing.com Australia

May 12, 2026

Earnings call transcript: ADMA Biologics Q1 2026 results miss expectations - Investing.com

May 12, 2026

May 11, 2026

ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation - marketscreener.com

May 11, 2026

$ADMA Investigation Reminder: ADMA Biologics Investigation - GlobeNewswire

May 11, 2026